Outcome of Board Meeting held on 29th August, 2026

Reg Office: G2 & G3 Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai – 400099 Email Id: bacilpharma07@gmail.com, CIN: L24200MH1987PLC043427, Tel: 22618452/22661541, Date: August 29th, 2026. BSE Limited, Listing Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400001. Ref: Scrip Code: 524516 Sub: Outcome of Board Meeting dated August 29, 2026. Dear Sir, Pursuant to provisions of Regulation 30 & Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at their Meeting held today (i.e. Saturday, August 29, 2026) considered the following matters: 1. 39th Annual General Meeting of the Company: The Board approved the Notice of the (39th) Annual General Meeting of the Company to be held on Wednesday, September 23rd, 2026 at 3:00 p.m. 2. Director’s Report for Financial Year ended March 31, 2026: The Director’s Report for the financial year ended March 31, 2026 along with the Annexures was approved by the Board. 3. 39th Annual General Meeting: The 39th Annual General Meeting of the Company will be held on Wednesday, September 23rd, 2026 at 3:00 p.m. IST through Video Conferencing (“VC”) / Other Audio Visual Means (“OAVM”) and in accordance with the relevant Circulars issued by The Ministry of Corporate Affairs and Securities and Exchange Board of India to transact the business as contained in the Notice convening the Annual General Meeting. The Meeting of the Board of Directors of the Company commenced at 12:05 p.m. and concluded at 01:00 p.m. Kindly take the same on record and acknowledge. Thanking You. For BACIL PHARMA LIMITED CHAITALI KALPATARU SHAH DIRECTOR & CFO DIN: 11167778 Encl.: as above 39TH ANNUAL REPORT 2025-26 BACIL PHARMA LIMITED CIN: L24200MH1987PLC043427 G2 & G3 Samarpan Complex, Next to Mirador Hotel, Opp Satam Wadi, Chakala, Sahar P & T Colony, Andheri East, Mumbai – 400099 BACIL PHARMA LIMITED ANNUAL REPORT 2025-26 BOARD OF DIRECTORS & KMP REGISTERED OFFICE  PRAKASH BHOORCHAND SHAH Office G2/G3, Samarpan Complex, Next To (Director) Mirador Hotel, Link Road, Opp Satam Wadi, (Resigned dated 22.07.2025) Chakala, Andheri (East), Sahar P & T Colony, Mumbai, Maharashtra, India, 400099  DINESH CHANDER NOTIYAL Email: bacilpha@yahoo.com (Non-Executive Director) CIN: L24200MH1987PLC043427 (Resigned dated 09.07.2026) Website : https://bacilpharma.co.in  AVANI SAVJIBHAI GODHANIYA (Non-Executive Director) BANKERS (Resigned on dated 09.07.2026) Union Bank of India Mumbai Samachar Marg,  CHAITALI KALPATARU SHAH Mumbai – 400 023 (Executive Director) (Appointed on dated 16.07.2025) SHARE TRANSFER AGENT  CHAITALI KALPATARU SHAH BIG SHARE SERVICES PVT. LTD. (Chief Financial Officer) E-2/3, Ansa Industrial Estate, (Appointed on dated 16.07.2025) Sakivihar Road, Saki Naka, Andheri (East), Mumbai – 400 072  JAYESH RAMCHANDRA PATIL Phone: 28470652, 28470653, 28473747, 28473474 Fax: 28475207 (Chief Financial Officer) (Resignation on dated 11.07.2025) www.bigshareonline.com  DIKSHANT SINGH PANWAR (Company Secretary) (Appointed dated 19.12.2025)  VIVEK MUKESH YADAV (Non-Executive Independent Director)  OMPRAKASH PYARELAL SONAR (Non-Executive Independent Director)  ANIL SINGH (Non-Executive Director) Appointed Dated on 25.08.2026)  Mahesh Singh (Non-Executive Independent Director) Appointed Dated on 25.08.2026) AUDITORS LAXMIKANT KABRA & CO LLP., (Resigned Auditor) (Resigned dated 12.08.2025) BACIL PHARMA LIMITED ANNUAL REPORT 2025-26 SARANG SHIVAJIRAO CHAVAN AND ASSOCIATES Chartered Accountants INTERNAL AUDITOR Mr. DIKSHANT SINGH PANWAR Company Secretary SECRETARIAL AUDITOR M/s. Ramesh Chandra Bagdi & Co., Practicing Company Secretary Mumbai 39th Annual General Meeting CONTENTS Page No. Date : September 23, 2026 Notice to the Members 4 (Wednesday) Directors’ Report 26 Corporate Governance Report Time : 03:00 P.M. (IST) Management Discussion and 49 Analysis THROUGH VIDEO CONFERENCING (VC) 52 AGM : Secretarial Audit Report / OTHER AUDIO-VISUAL MEANS Venue (OAVM) Independent Auditors Report 58 Balance Sheet 69 Statement of Profit and Loss 70 Cash Flow Statements 71 BACIL PHARMA LIMITED ANNUAL REPORT 2025-26 NOTICE NOTICE IS HEREBY GIVEN THAT THE THIRTY-NINE ANNUAL GENERAL MEETING OF BACIL PHARMA LIMITED WILL BE HELD ON 23RD SEPTEMBER, 2026 AT 03:00 P.M. THROUGH VIDEO CONFERENCING (VC) / OTHER AUDIO-VISUAL MEANS (OAVM) TO TRANSACT THE FOLLOWING BUSINESS: ORDINARY BUSINESS 1. To receive, consider and adopt the Audited Financial Statements of the Company for the Financial Year ended March 31st, 2026, including the Audited Balance Sheet as at March 31st, 2026, the Statement of Profit and Loss & Cash Flow Statement for the Year ended on that date together with the Reports of the Board of Directors and Auditors there on. To consider and, if thought fit, to pass the following resolution as an Ordinary Resolution: “RESOLVED THAT the audited standalone financial statements of the Company for the financial year ended March 31, 2026, together with the Reports of the Board of Directors and Auditors thereon, be and are hereby received, considered and adopted. 2. To appoint a Director in place of Ms. Chaitali Kalpataru Shah (DIN: 11167778), who retires by rotation at this Annual General Meeting and being eligible, offers herself for re-appointment. To consider and, if thought fit, to pass the following resolution as an Ordinary Resolution: “RESOLVED THAT pursuant to the provisions of Section 152 and other applicable provisions of the Companies Act, 2013, the approval of the member of the company be, and is hereby accorded to their appointment of Ms. Chaitali Kalpataru Shah (DIN: 11167778), as a director, to extent that he is required to retire by rotation.” SPECIAL BUSINESS 3. Change in Designation of Ms. Chaitali Kalpataru Shah (DIN: 11167778) from Executive Director to Managing Director of the Company To consider and if deemed fit, to pass with or without modification(s), the following resolution as a Special Resolution: “RESOLVED THAT pursuant to the provisions of Sections 196, 197, 198, 203 and other applicable provisions of the Companies Act, 2013 read with Schedule V and the Rules made thereunder, including any statutory modification(s) or re-enactment(s) thereof for the time being in force, and the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Articles of Association of the Company, and based on the recommendation of the Nomination and Remuneration Committee and the Board of Directors of the Company, the consent of the Members be and is hereby accorded for change in designation of Ms. Chaitali Kalpataru Shah (DIN: 11167778) from Executive Director to Managing Director of the Company, with effect from 25th August, 2026, for the remaining period of her existing tenure, i.e. up to 28th July, 2029, on such terms and conditions and remuneration as set out in the Statement annexed to the Notice and as may be determined by the Board of Directors, subject to the applicable provisions of the Companies Act, 2013 and other applicable laws. RESOLVED FURTHER THAT the Board of Directors of the Company, including the Nomination and Remuneration Committee thereof, be and is hereby authorised to revise, BACIL PHARMA LIMITED ANNUAL REPORT 2025-26 alter, vary or modify the terms and conditions of appointment and remuneration of Ms. Chaitali Kalpataru Shah, including remuneration, within the limits prescribed under the Companies Act, 2013 and other applicable laws. RESOLVED FURTHER THAT in the event the Company has no profits or its profits are inadequate in any financial year during the tenure of Ms. Chaitali Kalpataru Shah as Managing Director, the remuneration payable to her shall be governed by and subject to the applicable provisions of Schedule V to the Companies Act, 2013 and other applicable laws. RESOLVED FURTHER THAT any Director and/or the Co [Showing first 8,000 characters — download PDF for full document]